Akums Drugs and Pharmaceuticals Limited has released its financial results for Q2 FY25, showing mixed performance metrics.
Key Financial Highlights:
You might also like
- Revenue from Operations:
- For the quarter ended September 30, 2024, revenue stood at ₹1,033.09 crore, down by 12.5% from ₹1,181.24 crore in the same period last year.
- Compared to the previous quarter (₹1,019.13 crore), revenue showed a marginal increase of 1.4%.
- Net Profit:
- The profit for the quarter reached ₹66.65 crore, marking a significant 103.8% increase YoY from ₹32.69 crore in Q2 FY24.
- On a QoQ basis, profit rose by 8.9% from ₹61.21 crore in Q1 FY25.
- Half-Year Performance:
- For the six months ended September 30, 2024, Akums reported revenue of ₹2,052.20 crore, slightly down from ₹2,151.14 crore in the previous year.
- Profit for the six-month period was ₹127.86 crore, rebounding from a loss of ₹154.73 crore in the same period last year.
These results reflect Akums Drugs’ strategic adjustments to improve profitability despite a decline in revenue.
Disclaimer: This report is for informational purposes only and should not be considered as financial advice.
